IVI RMA North America, one of the largest fertility treatment networks in North America, has unveiled AiVA, an artificial intelligence assistant integrated into its proprietary Artemis clinical technology platform, as part of an effort to streamline reproductive medicine workflows and support more personalised patient care. Announced on October 8, 2026, the development builds on an established digital platform already deployed at more than 60 clinics, with approximately 2,000 users accessing Artemis during a typical workday.
The system combines longitudinal fertility treatment records, clinical documentation, laboratory information, patient communications and operational intelligence within a shared technology environment. AiVA is designed to help physicians retrieve relevant information from complex patient histories, identify potentially useful patterns from previous cases and reduce time spent on administrative activities. IVI RMA estimates that its ambient documentation tool, AiVA Talk, could save individual physicians between 35 and 110 minutes daily, depending on patient volume.
The announcement represents a significant operational development for a fertility network spanning more than 70 clinics and 27 in vitro fertilisation laboratories across North America. Rather than introducing a standalone AI application for embryo selection or laboratory image interpretation, IVI RMA is embedding artificial intelligence into the clinical information systems that support consultations, treatment planning, communication and everyday practice management.
However, the company has not disclosed a controlled clinical validation study demonstrating that AiVA improves pregnancy rates, live birth outcomes or the accuracy of fertility treatment decisions. Its reported time savings are estimates rather than independently established productivity results, while the precise effect on patient outcomes remains unquantified. The distinction makes Artemis an important healthcare technology deployment whose clinical and operational value will need to be assessed as adoption expands.
Thomas Molinaro, chief medical officer of IVI RMA North America, explained that the organisation developed Artemis specifically to address the complexity of fertility care and provide clinicians with tools aligned with its established treatment workflows. The platform is intended to evolve alongside medical teams and patient needs, with artificial intelligence providing additional support for accessing information and managing clinical responsibilities.
How does the Artemis and AiVA AI platform bring together fragmented fertility treatment records?
Fertility treatment involves a combination of laboratory measurements, ultrasound findings, medication protocols, embryology reports, previous treatment cycles and clinical consultations. These records may be generated by different departments and stored in systems that do not always present information as a complete, easily accessible patient history. For physicians managing multiple treatment cycles, reviewing fragmented records can consume substantial time before an appointment or treatment decision.
Artemis is designed to bring these information sources into a unified environment, while AiVA adds an AI-assisted layer for retrieving, summarising and interpreting relevant clinical information. According to IVI RMA, the assistant can combine previous treatment cycles, laboratory results, embryology data, clinical notes and outside medical records to present a more accessible patient overview. The organisation also says the platform can identify patterns and connections using insights drawn from hundreds of thousands of previous cases and the collective experience of more than 100 fertility specialists.
The ability to retrieve relevant information across a large clinical network could be particularly useful for patients who have undergone multiple unsuccessful treatment cycles or received care at different facilities. Previous stimulation protocols, ovarian responses, laboratory findings and treatment histories may all influence subsequent clinical discussions. A system that makes this information easier to access could help physicians assess available evidence more efficiently without replacing individual medical judgement.
However, access to historical data is not equivalent to validated predictive performance. The announcement does not specify the AI models used, the clinical questions against which they were tested or their accuracy in identifying treatment-relevant patterns. It also does not establish that recommendations generated from previous patient records improve reproductive outcomes, making independent clinical assessment essential.
Can AiVA Talk genuinely save fertility physicians between 35 and 110 minutes each day?
One of the most commercially relevant features is AiVA Talk, which uses ambient artificial intelligence to support clinical documentation. Ambient AI systems are designed to capture relevant information during clinical encounters and produce structured documentation, potentially reducing the need for physicians to prepare notes manually after appointments. IVI RMA estimates that the technology could save individual clinicians between 35 and 110 minutes per day, depending on their consultation workload.
The potential operational benefit extends beyond reducing the time required to prepare medical records. AiVA can draft consultation notes, patient messages, clinical summaries and follow-up plans in formats preferred by individual providers. If these functions reduce repetitive documentation without compromising accuracy, physicians may have greater capacity for consultations, patient questions and clinical review.
The estimated saving of almost two hours at the upper end is substantial, but the announcement does not describe the methodology used to calculate it. IVI RMA has not disclosed a formal time-and-motion study, the number of physicians included in its assessment or a comparison against conventional documentation workflows. The figures should therefore be understood as company estimates rather than independently demonstrated efficiency gains.
The quality of AI-generated documentation will also influence whether projected savings translate into routine practice. Physicians must be able to identify transcription errors, incorrect medication details, missing clinical information and misleading summaries before notes enter the permanent medical record. Time spent reviewing and correcting generated content may offset some of the initial savings, particularly during early implementation.
A meaningful assessment would compare total documentation time before and after deployment, including the time required for corrections. It would also examine note completeness, physician satisfaction and whether administrative improvements translate into increased patient-facing capacity. These measures could provide stronger evidence of operational value than estimates based on potential time savings alone.
How could Artemis Care Compass and Messenger improve the fertility patient experience?
Artemis includes several patient-facing and care-coordination capabilities alongside its clinical intelligence features. Artemis Care Compass is designed to help providers guide patients through personalised treatment plans and identify upcoming steps, while Artemis Messenger enables communication between patients and care teams within the platform. Artificial intelligence also assists with extracting and summarising documents, potentially reducing the effort involved in managing records and communications.
These functions address practical aspects of fertility treatment, where patients may need repeated appointments, laboratory assessments, medication instructions and communication with different members of a care team. Delays in receiving information or uncertainty about treatment schedules can create additional administrative burdens for both patients and providers. More coordinated digital communication may help reduce unnecessary exchanges and provide clearer visibility into scheduled activities.
The existing Artemis Patient Portal offers access to treatment-cycle information, laboratory results, ultrasound images, appointment details and educational resources. Patients can also communicate with their care teams, review medication schedules and maintain personal cycle journals. These established functions provide an important distinction: the October announcement introduces additional AI capabilities within a broader digital environment rather than representing the first availability of online fertility records or patient messaging.
Patient experience improvements will depend on whether the system delivers timely, accurate and understandable information. Fertility treatment can involve emotionally sensitive discussions and clinical decisions that are not adequately addressed through automated summaries alone. AI-generated communications must therefore support clinical relationships rather than creating confusion about whether a message has been reviewed or authorised by a healthcare professional.
IVI RMA has not released comparative patient satisfaction results, communication response-time data or treatment-adherence outcomes specifically attributable to AiVA. The platform’s ability to provide a unified communication environment is established through its described functionality, but the scale of its patient-experience benefits remains to be measured.
Why will data privacy and clinical oversight be essential for AI-powered reproductive medicine?
The use of longitudinal patient records creates important data governance requirements, particularly when information is drawn from fertility histories, laboratory findings and previous treatment cycles. Reproductive medicine records can contain sensitive personal information, including genetic testing results, gamete and embryo information, reproductive intentions and details about partners or donors. Combining these records within AI-enabled systems increases the importance of clearly defined access permissions and appropriate use of patient information.
In the United States, healthcare providers and relevant technology partners must comply with applicable federal and state privacy requirements, including the Health Insurance Portability and Accountability Act where it applies. Federal guidance makes clear that certain third-party AI services handling protected health information may qualify as business associates, with corresponding contractual and security obligations. These requirements apply to the nature of the data processing and business relationships rather than simply whether a product is described as an AI assistant.
IVI RMA has not publicly detailed the complete AiVA model architecture, training-data governance framework, external technology dependencies or independent cybersecurity assessments in its October announcement. The absence of those details does not establish that the system lacks appropriate controls, but it limits external assessment of how sensitive information is protected. As Artemis expands internationally, differing privacy and data protection requirements will create additional implementation considerations.
Clinical governance is equally important because AI-generated summaries can influence how information is presented to physicians. A system that omits relevant treatment history or incorrectly interprets a laboratory finding could introduce errors even when it does not independently prescribe treatment. Maintaining traceable links between AI-generated statements and the underlying medical records would help clinicians verify important information before relying on it.
The United States Food and Drug Administration’s January 2026 clinical decision support guidance also provides relevant regulatory context. Certain administrative, record-management and clinical support functions may fall outside the definition of a regulated medical device, while other software functions can remain subject to device requirements depending on their intended use and operation. The announcement does not establish an FDA clearance or approval for AiVA, nor does it provide sufficient detail to classify every function under the applicable regulatory framework.
Does the Artemis launch demonstrate that artificial intelligence improves IVF success rates?
The October announcement does not provide evidence that Artemis or AiVA increases implantation rates, clinical pregnancy rates or live birth rates. This distinction is important because operational healthcare technology and clinical decision-making algorithms require different forms of evaluation. A platform may improve access to information or documentation efficiency without directly changing the effectiveness of fertility treatment.
The broader reproductive medicine industry has been investigating artificial intelligence for embryo assessment, image interpretation, treatment prediction and laboratory workflow management. However, those applications should not be confused with the specific functions disclosed for AiVA. IVI RMA describes its new assistant primarily in terms of clinical information access, documentation, communication and organisational intelligence rather than an authorised autonomous embryo-selection system.
In its 2026 committee opinion on artificial intelligence in the IVF laboratory, the American Society for Reproductive Medicine cautioned that retrospective evidence alone is insufficient to establish improved clinical outcomes. The society emphasised the importance of prospective validation and randomised trials when evaluating AI applications intended to influence embryo selection or reproductive outcomes. Its guidance concerns laboratory AI rather than a direct assessment of Artemis, but the underlying distinction between technical performance and demonstrated patient benefit remains relevant.
For Artemis, suitable validation would depend on the particular function being assessed. Documentation capabilities could be evaluated through accuracy, completeness and correction rates, while information retrieval tools could be tested against independently reviewed clinical records. Any future functions making treatment recommendations would require evidence appropriate to their intended clinical role and the consequences of an incorrect recommendation.
This creates an opportunity for IVI RMA to build a differentiated evidence base around its technology. Given the scale of its network, the organisation could evaluate performance across multiple clinics and physician groups, provided studies appropriately address patient selection, differences in existing workflows and potential sources of bias. The announcement does not confirm that such a prospective validation programme is underway.
How does the Artemis deployment support IVI RMA’s wider fertility network strategy?
Artemis is already deployed at more than 60 clinics across North America, indicating that the underlying platform has progressed beyond a limited pilot. IVI RMA reported approximately 2,000 daily users and said a team of nearly 34 engineers has been developing, testing, deploying and maintaining the platform and its associated tools. The company described AiVA’s introduction as part of a rollout across its United States network, without establishing that every AI feature is already operational at every Artemis location.
The organisation’s North American network includes Reproductive Medicine Associates, Boston IVF and Toronto-based TRIO, spanning more than 70 clinics and 27 IVF laboratories. IVI RMA North America reports that its clinical network has contributed to pregnancies resulting in more than 220,000 births and has produced more than 1,000 scientific publications. These historical achievements establish the organisation’s scale and research experience, but they should not be interpreted as outcomes attributable to the newly introduced AI technology.
The broader IVI RMA Global network operates more than 200 locations across 15 countries and employs over 6,000 people. Management plans to expand Artemis throughout this international network in the coming years, creating the possibility of a common technology infrastructure across geographically separated fertility operations. However, the company has not disclosed a detailed country-by-country implementation schedule or a committed completion date.
A shared platform could make it easier to standardise documentation, coordinate specialist knowledge and compare operational performance across clinics. Such consistency may be valuable for large fertility groups where clinical teams use different procedures and information systems. Nevertheless, deploying the same technology across different jurisdictions will require attention to local medical practice, patient consent, language, data protection and laboratory workflows.
The network’s size also creates an opportunity to assess variation in AI performance across different clinical settings. A documentation tool that works well in one clinic may require adjustment for different consultation styles or treatment processes elsewhere. Successful international expansion will therefore depend on local validation and continued monitoring, not simply installation of the same software.
What role will Artemis Insights and Pulse Check play in managing fertility clinic operations?
Beyond direct clinical support, Artemis includes tools designed to improve operational visibility across the organisation. Artemis Insights provides leadership with information about clinical and operational trends, while Artemis Pulse Check uses AI to identify patterns in patient feedback and areas where the care experience may be improved. These functions extend the platform’s reach into organisational management rather than remaining confined to electronic medical records.
Lynn Mason, chief executive officer of IVI RMA North America, identified the shared technology environment as a way to connect knowledge across the network and use patient experience information to support continuing service improvements. The intended approach combines clinical data with operational and communication insights, potentially allowing leadership teams to identify issues affecting multiple clinics rather than relying exclusively on individual reports.
The value of these capabilities will depend on the reliability of the underlying data and the quality of the recommendations generated. Patient feedback can identify recurring concerns about appointments, communication or administrative processes, but it may not represent every patient population equally. AI-generated trends should therefore be interpreted alongside established quality measures and direct input from clinical and operational teams.
The company has not released quantitative results showing improvements in appointment access, operational expenditure, patient retention or care coordination following Artemis Insights or Pulse Check deployment. These remain areas where measurable performance indicators could help establish the platform’s operational contribution.
What must IVI RMA demonstrate as AiVA expands across its fertility care network?
The introduction of AiVA marks a further stage in IVI RMA’s development of Artemis, moving from a shared fertility technology infrastructure towards AI-assisted clinical information retrieval, documentation and organisational support. With more than 60 clinics already using the underlying platform, the company has an established deployment base from which to evaluate its new capabilities. However, a large number of users does not independently demonstrate improved clinical performance or verify the projected physician time savings.
The immediate operational measures will include actual documentation time saved, the frequency of AI-generated errors, physician utilisation and changes in patient communication efficiency. Evaluating performance across multiple clinics would also help determine whether benefits are consistent or depend heavily on individual working practices. Such evidence could clarify whether AiVA provides a sustainable productivity advantage rather than a temporary improvement associated with introducing new software.
For reproductive medicine, the longer-term opportunity is to make complex patient histories easier to interpret while maintaining clinical accountability. The combination of historical treatment records, specialist expertise and digital care coordination could support more informed consultations, but any claims about improving fertility outcomes will require direct clinical evidence.
IVI RMA’s next meaningful achievement will therefore be demonstrating that its technology produces measurable improvements in everyday care without compromising documentation accuracy, patient confidentiality or medical oversight. Artemis has already established a substantial deployment footprint, and AiVA adds new capabilities to that infrastructure. The success of the initiative will ultimately depend on whether the organisation can convert its technological scale into independently measurable improvements in clinician efficiency, patient experience and the quality of reproductive healthcare delivery.